
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova has shown a positive financial trajectory, with a year-over-year operating margin increase of 180 basis points, driven by enhanced gross margins and effective management of selling, general, and administrative expenses. The company posted mid-single-digit revenue growth of 6.7% for 2024 and anticipates organic growth in the cardiopulmonary segment of 7.0-8.0% for 2025, spurred by the launch of the Essenz HLM and gains in oxygenator market share. Additionally, LivaNova's capacity for oxygenators has been improved by 10% in 2024, with expectations of a further 10-15% increase in capacity for 2025, positioning the company for continued revenue expansion.
Bears say
LivaNova's financial outlook appears negative due to slowing revenue growth in key segments, specifically in Neuromodulation and Cardiopulmonary divisions, where growth rates have significantly decreased compared to prior quarters. The company's recent guidance indicates a potential revenue growth deceleration to low-single digits, which aligns with challenges in the U.S. and international epilepsy markets stemming from personnel changes. Additionally, pressure on operating margins and expectations for below-consensus earnings contribute to concerns regarding overall financial performance.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares